PL EN


Preferences help
enabled [disable] Abstract
Number of results
2005 | 52 | 2 | 301-310
Article title

Design of vascular endothelium-specific drug-targeting strategies for the treatment of cancer.

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
Tumor endothelial cells are actively involved in the neovascularization processes that accompany tumor growth. Their easy accessibility for systemically applied therapeutics makes them interesting targets for therapeutic intervention. Especially for drug targeting-based therapeutics that often consist of macromolecular moieties, the tumor endothelium is considered a much better target than the tumor cells located behind the vascular wall barrier. In this review, the general principles underlying the development and choices in the development of vascular drug-targeting strategies are discussed. An overview of target epitopes identified in the past two decades is followed by a summary of those strategies that directly or indirectly induced tumor blood flow blockade in vivo. The demonstrated therapeutic success in pre-clinical animal models in debulking large tumor masses and inhibiting tumor outgrowth warrant further development of these therapeutic approaches. Yet, more effort should be put in studies in which the efficacy of different effector activities aimed at the same target, of one effector activity aimed at different targets, and of multiple target strategies are be compared. Combining these data with proper inventories on the molecular basis of tumor endothelial heterogeneity in general will make possible the development of tumor vascular drug-targeting strategies towards clinical application.
Publisher

Year
Volume
52
Issue
2
Pages
301-310
Physical description
Dates
published
2005
received
2005-04-05
revised
2005-06-08
accepted
2005-06-10
Contributors
  • University Medical Center Groningen, University of Groningen, Department Pathology and Laboratory Medicine, Medical Biology section, Endothelial Cell and Vascular Drug-targeting Research, Groningen, Netherlands
References
  • Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
  • Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59: 183-188.
  • Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
  • Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102: 4384-4392.
  • Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164.
  • Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255-1262.
  • Burrows FJ, Tazzari PL, Amlot P, Gazdar AF, Derbyshire EJ, King SW, Vitetta ES, Thorpe PE (1995) Endoglin is an endothelial cell proliferation marker that is selectively expressed in tumor vasculature. Clin Cancer Res 1: 1623-1634.
  • Burrows FJ, Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90: 8996-9000.
  • Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
  • Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99: 1659-1665.
  • Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97: 14608-14613.
  • Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P, Dejana E (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100: 905-911.
  • Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23: 217-225.
  • Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
  • Epstein AL, Khawli LA, Hornick JL, Taylor CR (1995) Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res 55: 2673-2680.
  • Everts M, Koning GA, Kok RJ, Asgeirsdottir SA, Vestweber D, Meijer DKF, Storm G, Molema G (2003) In vitro cellular handling and in vivo targeting of E-selectin directed immunoconjugates and immuno-liposomes used for drug delivery to inflamed endothelium. Pharm Res 20: 64-72.
  • Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ (2003) Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 30: 260-268.
  • Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
  • Forster-Horvath C, Meszaros L, Raso E, Dome B, Ladanyi A, Morini M, Albini A, Timar J (2004) Expression of CD44v3 protein in human endothelial cells in vitro and in tumoral microvessels in vivo. Microvasc Res 68: 110-118.
  • Hagemeier HH, Vollmer E, Goerdt S, Schulze Osthoff K, Sorg C (1986) A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer 38: 481-488.
  • Hallahan DE, Staba Hogan MJ, Virudachalam S, Kolchinsky A (1998) X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res 58: 5216-5220.
  • Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153: 543-553.
  • Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249-8255.
  • Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407.
  • Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL (2003) Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 63: 5046-5053.
  • Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547-550.
  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
  • Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685-693.
  • Kalluri R (2003) Basement membranes: structure assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433.
  • Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP (2001) Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7: 811-822.
  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
  • Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17: 768-774.
  • Kok RJ, Ásgeirsdóttir SA, Verweij WR (2001) Development of proteinaceous drug-targeting constructs using chemical and recombinant DNA approaches. In Drug-Targeting - Organ Specific Strategies, Molema G, Meijer DKF, eds. pp 275-308, Wiley-VCH, Weinheim, New York.
  • Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Ásgeirsdóttir SA, Everts M, Meijer DKF, Molema G (2002) Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug Chem 13: 128-135.
  • Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ (2002) Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195: 1575-1584.
  • Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
  • Mavria G, Porter CD (2001) Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment. Gene Ther 8: 913-920.
  • Melkko S, Halin C, Borsi L, Zardi L, Neri D (2002) An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys 54: 1485-1490.
  • Molema G, Meijer DKF (2001) Drug-Targeting: Organ-Specific Strategies, Wiley-VCH, Weinheim.
  • Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-2816.
  • Mutuberria R, Arends JW, Griffioen AW, Hoogenboom HR (2001) Phage display technology for target discovery in drug delivery research. In Drug-Targeting - Organ Specific Strategies, Molema G, Meijer DKF, eds. pp 255-273, Wiley-VCH, Weinheim, New York.
  • Nguyen M, Strubel NA, Bischoff J (1993) A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365: 267-269.
  • Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99: 7009-7014.
  • Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61: 711-716.
  • Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429: 629-635.
  • Olson TA, Mohanraj D, Roy S, Ramakrishnan S (1997) Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 73: 865-870.
  • Paleolog EM (2002) Angiogenesis in rheumatoid arthritis. Arthritis Res. 4 Suppl 3: S81-S90.
  • Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727.
  • Pober JS (2002) Endothelial activation: intracellular signaling pathways. Arthritis Res 4 Suppl 3: S109-S116.
  • Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102: 430-437.
  • Ramsauer M, D’Amore PA (2002) Getting Tie(2)d up in angiogenesis. J Clin Invest 110: 1615-1617.
  • Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of solid Hodgkin’s tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58: 4646-4653.
  • Reinders ME, Sho M, Robertson SW, Geehan CS, Briscoe DM (2003) Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 171: 1534-1541.
  • Rettig WJ, Garin Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836.
  • Sato TN, Tozawa Y, Deutsch U, Wolburg Buchholz K, Fujiwara Y, Gendron Maguire M, Gridley T, Wolburg H, Risau W, Qin Y (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74.
  • Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria P, Woodle MC (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149.
  • Schlingemann RO, Rietveld FJ, De Waal RM, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, Ruiter DJ (1990) Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 62: 690-696.
  • Schraa AJ, Everts M, Kok RJ, Asgeirsdottir SA, Molema G (2002a) Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. Biotechnol Annu Rev 8: 133-165.
  • Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DKF, de Leij LFMH, Molema G (2002b) Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer 102: 469-475.
  • Schraa AJ, Kok RJ, Botter SM, Withoff S, Meijer DKF, de Leij LFMH, Molema G (2004) RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphav-beta3 expressing endothelial cells. Int J Cancer 112: 285.
  • Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA (2001) Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 98: 119-124.
  • St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes expressed in human tumor endothelium. Science 289: 1197-1202.
  • Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I (2004) Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351: 250-259.
  • Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA (1996) Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426-433.
  • Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood 94: 192-198.
  • Vane JR, Borne GVR, Welzel D (1995) The Endothelial Cell in Health and Disease. Schattauer Verlagsgesellschaft mbH. Stuttgart.
  • Von Andrian UH, Mackay CR (2000) T-cell function and migration. Two sides of the same coin. N Engl J Med 343: 1020-1034.
  • Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645-2650.
  • Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D (2004) Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 113: 885-894.
  • Willam C, Koehne P, Jurgensen JS, Grafe M, Wagner KD, Bachmann S, Frei U, Eckardt KU (2000) Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res 87: 370-377.
  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147.
  • Withoff S, Helfrich W, de Leij LFMH, Molema G (2001) Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther 3: 53-62.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv52i2p301kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.